SART3

Across TCGA pan-cancer cohorts, SART3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SART3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SART3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SART3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, CCRCC, and LSCC are the cancer types where SART3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SART3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.438	<.001	11	view →
CCRCC	Male	III,IV	+0.238	<.001	10	view →
LSCC	Male	II,III,IV	+0.344	<.001	8	view →
HNSC	Male	IV	+0.277	<.001	8	view →
LUAD	Male	All	+0.267	<.001	8	view →
PDAC	Female	II,III,IV	−0.267	<.001	5	view →
OV	All	All	+0.334	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SART3–COAD

Open the COAD breakdown →